91AV

Introduction

The ready availability of structurally novel lead molecules with appropriately controlled molecular properties (e.g. logP, molecular weight and fraction of sp3 atoms) is crucial to the ability of the pharmaceutical industry to bring new small molecule drugs to market. However, it is now recognised that access to such lead molecules is poorly served not only by many current commercial libraries but also by the synthetic methods widely adopted within industry and many of those developed in academic laboratories. In this meeting, approaches to rectifying this issue will be presented both from academia and industry, with the hope of stimulating a broader recognition of, and solutions to, the challenges of lead-oriented synthesis.

Deadlines

• Sep 04 2015
  Standard registration deadline

  

Useful links

Speakers

• Prof. Jeffrey Bode ETH Zurich, Switzerland
• Dr Ian Churcher GSK, United Kingdom
• Dr Jason Kettle AstraZeneca, United Kingdom
• Prof. Steve Marsden University of Leeds, United Kingdom
• Prof. Peter O'Brien University of York, United Kingdom
• Prof. David Spring University of Cambridge, United Kingdom

---

Venue

GSK Stevenage

GSK Stevenage, Gunnels Wood Road, Stevenage, SG1 2NY, United Kingdom

Organised by

EPSRC Dial-a-Molecule Grand Challenge Network

Contact information

Kelly Kilpin
Dial-a-Molecule Grand Challenge
+44 02380 597314
Contact us by email

---